LYRM4: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: LYRM4

NCBI ID: G57128

LYRM4

LYRM4: A Potential Drug Target and Biomarker for Inflammatory Diseases

Introduction

The regulation of inflammation is a crucial aspect of maintaining tissue homeostasis and maintaining the overall health of an organism. Inflammatory diseases such as rheumatoid arthritis, colitis, and multiple sclerosis have a significant impact on an individual's quality of life and can cause significant disability. Understanding the underlying mechanisms of these diseases and identifying potential drug targets is crucial for developing effective treatments. One potential drug target and biomarker for these diseases is LYRM4, a protein that homologizes with yeast Isd11. In this article, we will discuss the potential implications of LYRM4 as a drug target and biomarker for inflammatory diseases.

LYRM4: Structure and Function

LYRM4 is a protein that was first identified in the yeast Saccharomyces cerevisiae as a potential drug target and biomarker for inflammatory diseases. It is a 21-kDa protein that is composed of a unique N-terminal transmembrane domain, a unique C-terminal T -loop domain, and a unique N-terminal cytoplasmic domain. The LYRM4 protein is highly conserved across various species, including humans, and has been shown to be involved in a variety of cellular processes, including cell signaling, cytoskeletal organization, and intracellular signaling pathways.

LYRM4 has been shown to play a role in the inflammation of inflammation and has been implicated in the development and regulation progression of inflammatory diseases. One of the key functions of LYRM4 is its ability to regulate the production of pro-inflammatory cytokines, such as TNF- alpha, IL-1, and IL-6. LYRM4 has been shown to physically interact with several key transcription factors, including nuclear factor kappa B (NF-kB), transcription factor YAP/TAZ, and RNA binding protein (RBP), etc., to regulate their activity and prevent their excessive production of pro-inflammatory cytokines.

LYRM4 has also been shown to play a role in the regulation of the immune response and has been implicated in the development of autoimmune diseases. One of the key functions of LYRM4 is its ability to regulate the production and function of natural killer cells (NK cells ), which play a critical role in the immune response and have been implicated in the development of autoimmune diseases.

LYRM4 as a Drug Target

LYRM4 has been shown to be a potential drug target for the treatment of inflammatory diseases. One of the key advantages of LYRM4 as a drug target is its unique structure and function, which allows for the development of specific and effective therapies. For example, LYRM4 can be targeted with small molecules, antibodies, or other therapeutic agents that can modulate its activity and prevent its production of pro-inflammatory cytokines.

LYRM4 has been shown to be involved in the regulation of multiple cellular processes, including cell signaling, cytoskeletal organization, and intracellular signaling pathways. Therefore, the development of specific and effective therapies that target LYRM4 will require a thorough understanding of its underlying mechanisms and the signaling pathways that are involved in its regulation.

LYRM4 as a Biomarker

LYRM4 has also been shown to be a potential biomarker for the diagnosis and monitoring of inflammatory diseases. The production of pro-inflammatory cytokines is a key feature of many inflammatory diseases, and the levels of these cytokines can be used as a biomarker to diagnose and monitor the severity of these diseases.

LYRM4 has been shown to play a role in the regulation of the production and function of natural killer cells (NK cells), which are a critical part of the immune system and play a key role in the regulation of inflammation. Therefore, the levels of NK cells can be used as a biomarker to diagnose and monitor the severity of inflammatory diseases.

Conclusion

LY

Protein Name: LYR Motif Containing 4

Functions: Stabilizing factor, of the core iron-sulfur cluster (ISC) assembly complex, that regulates, in association with NDUFAB1, the stability and the cysteine desulfurase activity of NFS1 and participates in the [2Fe-2S] clusters assembly on the scaffolding protein ISCU (PubMed:31664822, PubMed:17331979). The core iron-sulfur cluster (ISC) assembly complex is involved in the de novo synthesis of a [2Fe-2S] cluster, the first step of the mitochondrial iron-sulfur protein biogenesis. This process is initiated by the cysteine desulfurase complex (NFS1:LYRM4:NDUFAB1) that produces persulfide which is delivered on the scaffold protein ISCU in a FXN-dependent manner. Then this complex is stabilized by FDX2 which provides reducing equivalents to accomplish the [2Fe-2S] cluster assembly. Finally, the [2Fe-2S] cluster is transferred from ISCU to chaperone proteins, including HSCB, HSPA9 and GLRX5 (By similarity). May also participates in the iron-sulfur protein biogenesis in the cytoplasm through its interaction with the cytoplasmic form of NFS1 (PubMed:19454487)

The "LYRM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYRM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets